Operating
Equity in earnings (losses) of equity method investees
ResMed Equity in earnings (losses) of equity method investees increased by 13.4% to $1.72M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 412.8%, from $335K to $1.72M. Over 3 years (FY 2021 to FY 2025), Equity in earnings (losses) of equity method investees shows an upward trend with a -31.2% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
First reportedQ1 2019
Last reportedQ3 2026Apr 30, 2026
Metric ID:
operating_income_loss_from_equity_method_investmentsHistorical Data
19 periods
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$1.31M | -$1.39M | -$1.91M | -$2.63M | -$2.56M | -$2.03M | -$2.83M | -$183K | -$2.23M | -$3.9M | $739K | $440K | $963K | $1.08M | $335K | $1.27M | $1.49M | $1.52M | $1.72M |
| QoQ Change | — | -5.8% | -38.1% | -37.3% | +2.6% | +20.8% | -39.3% | +93.5% | <-999% | -74.8% | +119.0% | -40.5% | +118.9% | +11.8% | -68.9% | +278.8% | +17.3% | +1.7% | +13.4% |
| YoY Change | — | — | — | — | -95.3% | -46.3% | -47.6% | +93.0% | +12.9% | -92.1% | +126.2% | +340.4% | +124.7% | +45.7% | -23.9% | — | +54.6% | +40.7% | +412.8% |
Range-$3.9M – $1.72M
CAGR+6.2%
Avg YoY Growth+67.6%
Median YoY Growth+43.2%
Current Streak4 quarters growth
Equity in earnings (losses) of equity method investees at Other Companies
Frequently Asked Questions
- What is ResMed's equity in earnings (losses) of equity method investees?
- ResMed (RMD) reported equity in earnings (losses) of equity method investees of $1.72M in Q1 2026.
- How has ResMed's equity in earnings (losses) of equity method investees changed year-over-year?
- ResMed's equity in earnings (losses) of equity method investees increased by 412.8% year-over-year, from $335K to $1.72M.
- What is the long-term trend for ResMed's equity in earnings (losses) of equity method investees?
- Over 3 years (2021 to 2025), ResMed's equity in earnings (losses) of equity method investees has grown at a -31.2% compound annual growth rate (CAGR), from -$11.21M to $3.64M.